<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36871016</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1601-5223</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Hereditas</Title><ISOAbbreviation>Hereditas</ISOAbbreviation></Journal><ArticleTitle>Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis.</ArticleTitle><Pagination><StartPage>9</StartPage><MedlinePgn>9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41065-023-00270-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is an autoimmune disorder which could lead to inflammation and fibrosis in various organs. Pulmonary fibrosis is a severe complication in patients with SLE. Nonetheless, SLE-derived pulmonary fibrosis has unknown pathogenesis. Of pulmonary fibrosis, Idiopathic pulmonary fibrosis (IPF) is a typicality and deadly form. Aiming to investigate the gene signatures and possible immune mechanisms in SLE-derived pulmonary fibrosis, we explored common characters between SLE and IPF from Gene Expression Omnibus (GEO) database.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We employed the weighted gene co-expression network analysis (WGCNA) to identify the shared genes. Two modules were significantly identified in both SLE and IPF, respectively. The overlapped 40 genes were selected out for further analysis. The GO enrichment analysis of shared genes between SLE and IPF was performed with ClueGO and indicated that p38MAPK cascade, a key inflammation response pathway, may be a common feature in both SLE and IPF. The validation datasets also illustrated this point. The enrichment analysis of common miRNAs was obtained from the Human microRNA Disease Database (HMDD) and the enrichment analysis with the DIANA tools also indicated that MAPK pathways' role in the pathogenesis of SLE and IPF. The target genes of these common miRNAs were identified by the TargetScan7.2 and a common miRNAs-mRNAs network was constructed with the overlapped genes in target and shared genes to show the regulated target of SLE-derived pulmonary fibrosis. The result of CIBERSORT showed decreased regulatory T cells (Tregs), na&#xef;ve CD4+ T cells and rest mast cells but increased activated NK cells and activated mast cells in both SLE and IPF. The target genes of cyclophosphamide were also obtained from the Drug Repurposing Hub and had an interaction with the common gene PTGS2 predicted with protein-protein interaction (PPI) and molecular docking, indicating its potential treatment effect.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study originally uncovered the MAPK pathway, and the infiltration of some immune-cell subsets might be pivotal factors for pulmonary fibrosis complication in SLE, which could be used as potentially therapeutic targets. The cyclophosphamide may treat SLE-derived pulmonary fibrosis through interaction with PTGS2, which could be activated by p38MAPK.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Transplantation Center, the 3rd Xiangya Hospital, Central South University, 138 Tongzipo Rd, Changsha, 410013, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tang</LastName><ForeName>Youzhou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephropathy, the 3rd Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Transplantation Center, the 3rd Xiangya Hospital, Central South University, 138 Tongzipo Rd, Changsha, 410013, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Qingtai</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Transplantation Center, the 3rd Xiangya Hospital, Central South University, 138 Tongzipo Rd, Changsha, 410013, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Linyong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Life Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5225-9282</Identifier><AffiliationInfo><Affiliation>Transplantation Center, the 3rd Xiangya Hospital, Central South University, 138 Tongzipo Rd, Changsha, 410013, Hunan, China. zhuangquansteven@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of National Health Ministry on Transplantation Medicine, 138 Tongzipo Rd, Changsha, 410013, Hunan, China. zhuangquansteven@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hereditas</MedlineTA><NlmUniqueID>0374654</NlmUniqueID><ISSNLinking>0018-0661</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054990" MajorTopicYN="Y">Idiopathic Pulmonary Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immune cell</Keyword><Keyword MajorTopicYN="N">MAPK</Keyword><Keyword MajorTopicYN="N">Pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36871016</ArticleId><ArticleId IdType="pmc">PMC9985223</ArticleId><ArticleId IdType="doi">10.1186/s41065-023-00270-3</ArticleId><ArticleId IdType="pii">10.1186/s41065-023-00270-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):Itc81&#x2013;itc96. doi: 10.7326/AITC202006020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. Autoimmun Rev. 2004;3(1):70&#x2013;75. doi: 10.1016/S1568-9972(03)00090-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-9972(03)00090-9</ArticleId><ArticleId IdType="pubmed">14871652</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady D, Berkowitz EA, Sharma A, Ackman JB, Bernheim A, Chung M, et al. CT morphologic characteristics and variant patterns of interstitial pulmonary fibrosis in systemic lupus erythematosus. Radiol Cardiothorac Imaging. 2021;3(4):e200625. doi: 10.1148/ryct.2021200625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.2021200625</ArticleId><ArticleId IdType="pmc">PMC8415141</ArticleId><ArticleId IdType="pubmed">34498003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah JR, D'Cruz DP. Pulmonary complications of systemic lupus erythematosus. Semin Respir Crit Care Med. 2019;40(2):227&#x2013;234. doi: 10.1055/s-0039-1685537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1685537</ArticleId><ArticleId IdType="pubmed">31137062</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards AJ, Talbot IC, Swinson DR, Hamilton EB. Diffuse pulmonary fibrosis and bilateral pneumothoraces in systemic lupus erythematosus. Postgrad Med J. 1975;51(602):851&#x2013;855. doi: 10.1136/pgmj.51.602.851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.51.602.851</ArticleId><ArticleId IdType="pmc">PMC2496139</ArticleId><ArticleId IdType="pubmed">1208295</ArticleId></ArticleIdList></Reference><Reference><Citation>Beresford MW, Cleary AG, Sills JA, Couriel J, Davidson JE. Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus. 2005;14(2):152&#x2013;158. doi: 10.1191/0961203305lu2073oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305lu2073oa</ArticleId><ArticleId IdType="pubmed">15751820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31(3):479&#x2013;488. doi: 10.1016/j.ccm.2010.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2010.05.001</ArticleId><ArticleId IdType="pubmed">20692540</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F, Li Y, Zhu Y, Li G, Lei F, Zhang S, et al. CX3CR1 might be a promising predictor of systemic lupus erythematosus patients with pulmonary fibrosis. Scand J Immunol. 2021;94(1):e13038. doi: 10.1111/sji.13038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13038</ArticleId><ArticleId IdType="pubmed">33665864</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielepkowicz-Go&#x17a;dzi&#x144;ska A, Fendler W, Robak E, Kulczycka-Siennicka L, G&#xf3;rski P, Pietras T, et al. The role of CXC chemokines in pulmonary fibrosis of systemic lupus erythematosus patients. Arch Immunol Ther Exp. 2015;63(6):465&#x2013;473. doi: 10.1007/s00005-015-0356-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-015-0356-8</ArticleId><ArticleId IdType="pubmed">26275808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielepkowicz-Go&#x17a;dzi&#x144;ska A, Fendler W, Robak E, Kulczycka-Siennicka L, G&#xf3;rski P, Pietras T, et al. Exhaled IL-8 in systemic lupus erythematosus with and without pulmonary fibrosis. Arch Immunol Ther Exp. 2014;62(3):231&#x2013;238. doi: 10.1007/s00005-014-0270-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-014-0270-5</ArticleId><ArticleId IdType="pmc">PMC4024123</ArticleId><ArticleId IdType="pubmed">24492930</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756&#x2013;2762. doi: 10.1172/JCI60323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60323</ArticleId><ArticleId IdType="pmc">PMC3408732</ArticleId><ArticleId IdType="pubmed">22850886</ArticleId></ArticleIdList></Reference><Reference><Citation>Schattner A, Aviel-Ronen S, Mark EJ. Accelerated usual interstitial pneumonitis, anti-DNA antibodies and hypocomplementemia. J Intern Med. 2003;254(2):193&#x2013;196. doi: 10.1046/j.1365-2796.2003.01144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2796.2003.01144.x</ArticleId><ArticleId IdType="pubmed">12859701</ArticleId></ArticleIdList></Reference><Reference><Citation>Jindal SK, Agarwal R. Autoimmunity and interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):438&#x2013;446. doi: 10.1097/01.mcp.0000170522.71497.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mcp.0000170522.71497.61</ArticleId><ArticleId IdType="pubmed">16093819</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. doi: 10.1186/1471-2105-9-559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091&#x2013;1093. doi: 10.1093/bioinformatics/btp101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp101</ArticleId><ArticleId IdType="pmc">PMC2666812</ArticleId><ArticleId IdType="pubmed">19237447</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, et al. HMDD v3.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2019;47(D1):D1013&#x2013;D10d7. doi: 10.1093/nar/gky1010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1010</ArticleId><ArticleId IdType="pmc">PMC6323994</ArticleId><ArticleId IdType="pubmed">30364956</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453&#x2013;457. doi: 10.1038/nmeth.3337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545&#x2013;15550. doi: 10.1073/pnas.0506580102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GM, Huey R, Olson AJ. Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics. 2008;8:8.14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19085980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Bryant SH, Cheng T, Wang J, Gindulyte A, Shoemaker BA, et al. PubChem BioAssay: 2017 update. Nucleic Acids Res. 2017;45(D1):D955&#x2013;Dd63. doi: 10.1093/nar/gkw1118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw1118</ArticleId><ArticleId IdType="pmc">PMC5210581</ArticleId><ArticleId IdType="pubmed">27899599</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451&#x2013;5465. doi: 10.1002/jcp.27486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27486</ArticleId><ArticleId IdType="pubmed">30471116</ArticleId></ArticleIdList></Reference><Reference><Citation>Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008;133(1):271&#x2013;280. doi: 10.1378/chest.07-0079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.07-0079</ArticleId><ArticleId IdType="pubmed">18187752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol. 2012;2012:854941. doi: 10.1155/2012/854941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/854941</ArticleId><ArticleId IdType="pmc">PMC3318206</ArticleId><ArticleId IdType="pubmed">22489252</ArticleId></ArticleIdList></Reference><Reference><Citation>Richez C, Blanco P, Rifkin I, Moreau JF, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine. 2011;78(2):124&#x2013;130. doi: 10.1016/j.jbspin.2010.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2010.09.005</ArticleId><ArticleId IdType="pubmed">20961794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, He Y, Zhai Z, Sun E. Programmed cell death pathways in the pathogenesis of systemic lupus erythematosus. J Immunol Res. 2019;2019:3638562. doi: 10.1155/2019/3638562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/3638562</ArticleId><ArticleId IdType="pmc">PMC6913273</ArticleId><ArticleId IdType="pubmed">31871956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ma H, Huang J, Dai Y. Characterization of the Phosphoproteome in SLE patients. PLoS One. 2012;7(12):e53129. doi: 10.1371/journal.pone.0053129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0053129</ArticleId><ArticleId IdType="pmc">PMC3532163</ArticleId><ArticleId IdType="pubmed">23285258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Song X, Liu Y. TRB3 regulates pulmonary interstitial fibrosis through the MAPK signaling pathway. Int J Clin Exp Pathol. 2019;12(9):3247&#x2013;3257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949843</ArticleId><ArticleId IdType="pubmed">31934168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18(12):1893&#x2013;1905. doi: 10.1517/13543780903321490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543780903321490</ArticleId><ArticleId IdType="pubmed">19852565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Gong Q, Pan X, Guo P, He L, You Y. Depletion of Fractalkine ameliorates renal injury and Treg cell apoptosis via the p38MAPK pathway in lupus-prone mice. Exp Cell Res. 2021;405(2):112704. doi: 10.1016/j.yexcr.2021.112704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2021.112704</ArticleId><ArticleId IdType="pubmed">34126056</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Deng W, Meng Q, Qiu X, Sun D, Dai C. CD8+iTregs attenuate glomerular endothelial cell injury in lupus-prone mice through blocking the activation of p38 MAPK and NF-&#x3ba;B. Mol Immunol. 2018;103:133&#x2013;143. doi: 10.1016/j.molimm.2018.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.09.006</ArticleId><ArticleId IdType="pubmed">30268079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol. 2009;29(6):738&#x2013;746. doi: 10.1007/s10875-009-9318-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-009-9318-4</ArticleId><ArticleId IdType="pubmed">19756990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HH, Zhou XL, Shi YL, Yang J. Roles of p38 MAPK and JNK in TGF-&#x3b2;1-induced human alveolar epithelial to mesenchymal transition. Arch Med Res. 2013;44(2):93&#x2013;98. doi: 10.1016/j.arcmed.2013.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2013.01.004</ArticleId><ArticleId IdType="pubmed">23376055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen K, Li R, Zhang X, Qu G, Li R, Wang Y, et al. Acetyl oxygen benzoate engeletin ester promotes KLF4 degradation leading to the attenuation of pulmonary fibrosis via inhibiting TGF&#x3b2;1-smad/p38MAPK-lnc865/lnc556-miR-29b-2-5p-STAT3 signal pathway. Aging (Albany NY) 2021;13(10):13807&#x2013;13821. doi: 10.18632/aging.202975.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202975</ArticleId><ArticleId IdType="pmc">PMC8202900</ArticleId><ArticleId IdType="pubmed">33929970</ArticleId></ArticleIdList></Reference><Reference><Citation>Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier. J Allergy Clin Immunol. 2018;142(6):1710&#x2013;1718. doi: 10.1016/j.jaci.2018.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2018.10.015</ArticleId><ArticleId IdType="pubmed">30367909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhang S. T cells in fibrosis and fibrotic diseases. Front Immunol. 2020;11:1142. doi: 10.3389/fimmu.2020.01142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01142</ArticleId><ArticleId IdType="pmc">PMC7333347</ArticleId><ArticleId IdType="pubmed">32676074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Xia H, Yao S. Regulatory T cells are a double-edged sword in pulmonary fibrosis. Int Immunopharmacol. 2020;84:106443. doi: 10.1016/j.intimp.2020.106443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106443</ArticleId><ArticleId IdType="pubmed">32334385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang T, Cai M, Zhu S, Song L, Wang Q. Expression and existence forms of mast cell activating molecules and their antibodies in systemic lupus erythematosus. Immun Inflamm Dis. 2022;10(2):235&#x2013;240. doi: 10.1002/iid3.567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.567</ArticleId><ArticleId IdType="pmc">PMC8767519</ArticleId><ArticleId IdType="pubmed">34784451</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimbori C, Upagupta C, Bellaye PS, Ayaub EA, Sato S, Yanagihara T, et al. Mechanical stress-induced mast cell degranulation activates TGF-&#x3b2;1 signalling pathway in pulmonary fibrosis. Thorax. 2019;74(5):455&#x2013;465. doi: 10.1136/thoraxjnl-2018-211516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2018-211516</ArticleId><ArticleId IdType="pubmed">30808717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-&#x3b3; production in patients with active disease. Arthritis Rheum. 2011;63(6):1698&#x2013;1706. doi: 10.1002/art.30313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30313</ArticleId><ArticleId IdType="pubmed">21370226</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito I, Perna F, Ponticiello A, Perrella M, Gilli M, Sanduzzi A. Natural killer cells in Bal and Peripheral blood of patients with idiopathic pulmonary fibrosis (IPF) Int J Immunopathol Pharmacol. 2005;18(3):541&#x2013;545. doi: 10.1177/039463200501800314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463200501800314</ArticleId><ArticleId IdType="pubmed">16164835</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: from back to the future, to the future and beyond. Joint Bone Spine. 2019;86(4):429&#x2013;436. doi: 10.1016/j.jbspin.2018.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2018.09.004</ArticleId><ArticleId IdType="pubmed">30243784</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38(10):1654&#x2013;1661. doi: 10.1016/j.biocel.2006.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.03.021</ArticleId><ArticleId IdType="pubmed">16713323</ArticleId></ArticleIdList></Reference><Reference><Citation>Caunt CJ, Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 2013;280(2):489&#x2013;504. doi: 10.1111/j.1742-4658.2012.08716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2012.08716.x</ArticleId><ArticleId IdType="pmc">PMC3594966</ArticleId><ArticleId IdType="pubmed">22812510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Reynolds JM, Chang SH, Martin-Orozco N, Chung Y, Nurieva RI, et al. MKP-1 is necessary for T cell activation and function. J Biol Chem. 2009;284(45):30815&#x2013;30824. doi: 10.1074/jbc.M109.052472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.052472</ArticleId><ArticleId IdType="pmc">PMC2781480</ArticleId><ArticleId IdType="pubmed">19748894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai T, Li Y, Chen M, Pan G, Wen X, Mai Z, et al. Heparin-binding epidermal growth factor contributes to COPD disease severity by modulating airway fibrosis and pulmonary epithelial-mesenchymal transition. Lab Investig. 2018;98(9):1159&#x2013;1169. doi: 10.1038/s41374-018-0049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-018-0049-0</ArticleId><ArticleId IdType="pubmed">29581578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumasawa F, Hashimoto S, Mizumura K, Takeshita I, Onose A, Jibiki I, et al. Mitogen-activated protein kinase (MAPK) regulates leukotriene D4-induced HB-EGF and ADAM12 expression in human airway smooth muscle cells. Asian Pac J Allergy Immunol. 2013;31(1):58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23517395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, An YM, Choi WH, Kim JM, Cho S, Yoo BR, et al. Pro-apoptotic Noxa is involved in ablative focal irradiation-induced lung injury. J Cell Mol Med. 2017;21(4):711&#x2013;719. doi: 10.1111/jcmm.13014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13014</ArticleId><ArticleId IdType="pmc">PMC5345661</ArticleId><ArticleId IdType="pubmed">27862899</ArticleId></ArticleIdList></Reference><Reference><Citation>Momtazi G, Lambrecht BN, Naranjo JR, Schock BC. Regulators of A20 (TNFAIP3): new drug-able targets in inflammation. Am J Physiol Lung Cell Mol Physiol. 2019;316(3):L456&#x2013;Ll69. doi: 10.1152/ajplung.00335.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00335.2018</ArticleId><ArticleId IdType="pubmed">30543305</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>